We have collected information about Viral Vector Drug Delivery for you. Follow the links to find out details on Viral Vector Drug Delivery.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507026/
Jul 06, 2012 · The transfer of genetic material through an appropriate vector, which can be a viral or nonviral vector, into the target tissue is in vivo delivery. This technique is the least advanced strategy at present but potentially it might be the most useful.
https://www.nature.com/articles/s41573-019-0012-9
Feb 01, 2019 · Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field.Author: Dan Wang, Phillip W. L. Tai, Guangping Gao
https://www.nih.gov/news-events/news-releases/drug-delivery-technology-leads-sustained-hiv-antibody-production-nih-study
Mar 09, 2020 · The drug-delivery system developed by scientists at NIAID’s Vaccine Research Center (VRC) uses adeno-associated virus serotype 8 (AAV8) to deliver an antibody gene. AAVs — small viruses that do not cause disease in humans — have proven to be safe, well-tolerated vectors …
https://www.sciencedirect.com/science/article/pii/S0168365916300979
Oct 28, 2016 · In addition, selection of the viral vector capable of transfer of therapeutic gene into target cells, along with long-term expression that avoids immunotoxicity has to be established. As with any drug development strategy, delivery of gene therapy has to be consistent and …Author: Krystof S. Bankiewicz, Vivek Sudhakar, Lluis Samaranch, Waldy San Sebastian, John Bringas, John Fors...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927556/
Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field.Author: Dan Wang, Phillip W. L. Tai, Guangping Gao
https://evolutionexec.com/news-analysis/cell-gene-therapies-increasing-demand-for-viral-vectors-drives-biomanufacturing-innovation-cdmo-investment/
Adeno-associated viral vectors (AAVs) are currently favoured, particularly for allogeneic approaches, due to their low immunogenicity, broad host range and low pathogenicity. The world’s first approved gene therapy ( Uniqure ’s Glybera) utilises an AAV1 vector to …
https://pharma.lonza.com/cell-and-gene-therapy/viral-vectors?q=%2Fcell-and-gene-therapy%2Fviral-vectors
Viral vector process development from concept to patient With more than 20 years of experience in manufacturing viral gene therapy products across various vector types, our team of scientists have in-depth technical expertise and comprehensive understanding to design and develop phase-appropriate, commercially viable manufacturing processes.
https://drug-dev.com/aav-vector-manufacturing-challenges-opportunities-in-the-manufacturing-of-aav-vectors-used-in-the-delivery-of-gene-therapy-treatments/
There remains a clear need for improved process productivities, and the need to develop manufacturing processes that can be applied to a wide number of AAV-based viral vector therapeutic candidates. Simplistically, the AAV vector is a delivery vehicle for a therapeutic gene, and the manufacturing process is not linked to that gene.
Searching for Viral Vector Drug Delivery?
You can just click the links above. The data is collected for you.
